Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2015
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 10 Dec 2013 Planned end date changed from 1 Feb 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 26 Jun 2012 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.